Suggested remit - To appraise the clinical and cost effectiveness of autologous haematopoietic stem cell transplantation (AHSTC) for previously treated relapsing-remitting multiple sclerosis.
Following on from information provided to NICE by the company in August 2017, the appraisal of Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1111
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 February 2023 | Discontinued. Following on from information provided to NICE by the company in August 2017, the appraisal of Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 01 May 2019 | Note added to the project documents |
| 27 July 2018 - 24 August 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 16 August 2017 | Note added to the project documents |
| 17 May 2017 (00:00) | Scoping workshop (London) |
| 28 March 2017 | Draft scope documents |
For further information on our processes and methods, please see our CHTE processes and methods manual